Abstract: Novel indane and indene derivatives are described which are endothelin receptor antagonists.

Abstract: A method of mobilizing hematopoietic stem cells from the bone marrow to the peripheral circulation is provided by administering to an animal an effective amount of mature, modified or multimeric forms of KC, gro&bgr;, gro&agr;, or gro&ggr;.

Abstract: The present invention is directed to a novel osmotic/effervescent system for the treatment of constipation and fecal impaction in a human or mammal in need thereof.

Abstract: This invention relates to novel compounds that can complex with lanthanide cations, processes for their preparation and the use of the resulting lanthanide chelates as biomolecular probes.

Abstract: A compound of formula (I) or a solvate thereof, characterized in that salt comprises a compound of formula (I) in anionic form and a salting cation; a process from preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.

Abstract: The present invention is directed to novel 4,5-disubstituted imidazole compounds, and compositions for use in therapy as an anti-inflammatory agent, and as an inhibitor of cytokine p38/MAP kinase mediated diseases.

Abstract: Dimeric cell-surface receptors in a subject are agonized by administering a metal chelated dimeric cell-surface receptor ligand formed by chelating a receptor binding moiety with a metal ion such as zinc, or by co-administering the receptor binding moiety and the metal ion. The binding moiety is a small organic molecule having a molecular weight of from about 100 to about 850, and metal chelation may form a symmetrical multimer such as a dimer of the receptor binding moiety. An example is bis{2,5-bis[2-benzimidazolylimino]-3a,6a-bis(2-pyridyl)-1,2,3,3a,4,5,6,6a-octahydroimidazo[4,5-d]imidazole-N,N′}-zinc(II). Dimeric cell surface receptors include granulocyte colony-stimulating factor, erythropoeitin receptor, macrophage-colony-stimulating factor, growth hormone receptor, thrombopoietin receptor, interferon alpha receptor, interferon beta receptor, tyrosine kinase receptor, insulin receptor and leptin receptor.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts and solvates: where R1 is hydrogen, C1-6alkyl (optionally substituted by hydroxy or C1-4alkoxy), phenyl-C1-4alkyl-, C1-6alkenyl, C1-6alkynyl; R2 is hydrogen or, up to three substituents selected from halogen, NO2, CN, N3, CF3O—, CF3S—, CF3SO2—, CF3CO—, C1-6alkyl, C1-6alkenyl, C1-6alkynyl, C1-6perfluoroalkyl, C3-6cycloalkyl, C3-6cycloalkyl-C1-4alkyl-, C1-6alkyl, C1-6alkylCO—, C3-6cycloalkylO—, C3-6cycloalkylCO—, C3-6cycloalkyl-C1-4alkylO—, C3-6cycloalkyl-C1-4alkylCO—, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C1-4alkyl-, C1-6alkylS—, C1-6alkylSO2—, (C1-4alkyl)2NSO2—, (C1-4alkyl)NHSO2—, (C1-4alkyl)2NCO—, (C1-4alkyl)NHCO— or CONH2; or —NR5R6 where R5 is hydrogen or C1-4alkyl, and R6 is hydrogen, C1-4alkyl, formyl, —CO2C1-4alkyl or —COC1-4alkyl; or two R2 groups together form a carbocyclic ring that is saturated or unsaturated, optionally inte

Abstract: The invention concerns a toothbrush with a bristle head or accessory unit which compensates for the brushing pressure and associated bending of the holder unit as well as hand movements. The toothbrush is characterized in that an O-ring or elastic shoe that is made either detached from or connected to the adjacent components is provided between the replaceable or fixed bristle unit and the holder unit. The bristle unit and holder unit are joined via a ball joint.

Abstract: This invention relates to substituted heteroanilide compounds which are modulators, agonists or antagonists, of the CCR5 receptior. In addition, this invention relates to the treatment and prevention of disease states mediatd by CCR5.

Abstract: The present invention provides a method for the treatment of bacterial, fungal, and viral infections by administering a truncated Gro&bgr;.

Abstract: This invention relates to a novel use of imidazole compounds in the treatment of CNS injuries.

Abstract: A method for normalising abnormally elevated ACTH release in mammals, such as humans, which method comprises the administration of an effective, non-toxic amount of a compound which regulates the biological activity of the arginine vasopressin V1b receptor (the AVP V1b receptor); a compound and composition for use in such method.

Abstract: The present invention pertains to improved adjuvant compositions comprising a mixture of a saponin adjuvant such as QS21 with monophosphoryl lipid A or derivative thereof such as 3D-MPL and interleukin 12. These compositions are useful in a range of prophylactic and therapeutic applications, particularly in vaccines, including cancer vaccines.

Abstract: The present invention relates to oil in water emulsion compositions, their use in medicine, in particular to their use in augmenting immune responses to a wide range of antigens, and to methods of their manufacture; the compositions having oil phase and an aqueous phase, a sterol and a saponin; the sterol being present in the oil phase and the saponin being present in the aqueous phase.

Abstract: The present invention relates to a novel pharmaceutical composition and process for preparing swallowable methylcellulose tablets that disintegrate rapidly and meet USP disintegration standards in 0.1N hydrochloric acid as well as water.